{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006084","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.009071+00:00","generated_at":"2026-06-18T11:24:00.103709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q4 core lung diag revenue $8.2M (+51% YoY); guides 2023 total rev $52-55M","bullets":["Total revenue Q4 $9.6M, FY2022 $38.2M; core lung diagnostic revenue $29.3M (+57% YoY).","Net loss Q4 $20.3M, FY2022 $65.4M; includes $7.0M loss on debt extinguishment/modification.","Cash and equivalents $43.1M at Dec 31, 2022; raised $65.7M net from debt/equity in Q4.","2023 total revenue guidance $52-55M, representing 36-44% growth over 2022 total revenue.","Biopharma services revenue $3.7M in FY2022 (-34% YoY); highest dollars under contract entering 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006084","json":"https://secwatch.observer/filing/0000950170-23-006084.json","markdown":"https://secwatch.observer/filing/0000950170-23-006084.md","text":"https://secwatch.observer/filing/0000950170-23-006084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/bdsx-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:24:00.103709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55feeb45fc7ff68f22b6cd1d5d3fe57f88e6419a","claim":"BIODESIX INC reported fourth quarter and fiscal 2022 results: revenue $9.6 million and $38.2 million, net income Net loss of $20.3 million and $65.4 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue of $9.6 million and $38.2 million for the fourth quarter and fiscal 2022, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal 2022"},{"label":"Revenue","value":"$9.6 million and $38.2 million"},{"label":"Net income","value":"Net loss of $20.3 million and $65.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ee38dcbe64761ccc2d710a338400456bd39a0bfa","claim":"BIODESIX INC updated its the fourth quarter and year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"On March 6, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm","confidence":0.67,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}